YOU STOPPED AT: LONG-TERM SURVEILLANCE EXPECTATIONS:

COMPLETING: LONG-TERM SURVEILLANCE EXPECTATIONS & YOUR FUTURE

Let me finish this critical section about what to expect over the next 5-10 years, and then provide your complete action plan moving forward.

---

LONG-TERM SURVEILLANCE EXPECTATIONS (2026-2036+)

YEARS 1-2 POST-RARP (2026-2027): INTENSIVE MONITORING PHASE
─────────────────────────────────────────────────────────────────

Why This Phase Matters:
✓ First 2 years are critical for detecting early recurrence
✓ Most recurrences occur within first 2-3 years
✓ Early detection = Better treatment outcomes
✓ Your baseline PSA is being established

Your Surveillance Schedule:
├─ PSA Testing: Every 6 months
├─ Oncology Visits: Every 6-12 months
├─ Imaging: Only if PSA elevated
├─ Digital Rectal Exam: At oncology visits
└─ Total Appointments: 4-6 per year

What You're Watching For:
✓ PSA remains ≤0.010 ng/mL (Excellent)
✓ No PSA elevation or doubling
✓ No new urinary symptoms
✓ No pelvic pain or discomfort
✓ No signs of recurrence

Expected Outcome (Most Likely - 85-90%):
✓ PSA remains undetectable
✓ No recurrence detected
✓ Proceed to less intensive monitoring
✓ Transition to annual surveillance by year 2-3

─────────────────────────────────────────────────────────────────

YEARS 3-5 POST-RARP (2028-2030): TRANSITION TO ANNUAL MONITORING
─────────────────────────────────────────────────────────────────

Why This Phase Matters:
✓ If no recurrence by year 3, risk decreases significantly
✓ Most recurrences detected by this point
✓ You can safely extend surveillance intervals
✓ Quality of life improves with less frequent testing

Your Surveillance Schedule:
├─ PSA Testing: Every 12 months (annual)
├─ Oncology Visits: Every 12 months
├─ Imaging: Only if PSA elevated
├─ Digital Rectal Exam: At oncology visits
└─ Total Appointments: 2 per year

What You're Watching For:
✓ PSA remains ≤0.010 ng/mL (Excellent)
✓ No PSA elevation or doubling
✓ No new symptoms
✓ Continued stability

Expected Outcome (Most Likely - 90%+):
✓ PSA remains undetectable
✓ No recurrence detected
✓ Continue annual surveillance indefinitely
✓ Significant peace of mind

─────────────────────────────────────────────────────────────────

YEARS 5-10 POST-RARP (2030-2035): LONG-TERM SURVEILLANCE
─────────────────────────────────────────────────────────────────

Why This Phase Matters:
✓ By year 5, if no recurrence, risk is very low
✓ Late recurrences (>5 years) are uncommon
✓ You're likely in "cancer survivor" phase
✓ Focus shifts to overall health and quality of life

Your Surveillance Schedule:
├─ PSA Testing: Every 12 months (annual)
├─ Oncology Visits: Every 12-24 months
├─ Imaging: Only if PSA elevated
├─ Digital Rectal Exam: At oncology visits
└─ Total Appointments: 1-2 per year

What You're Watching For:
✓ PSA remains ≤0.010 ng/mL (Excellent)
✓ No PSA elevation or doubling
✓ No new symptoms
✓ Continued stability

Expected Outcome (Most Likely - 95%+):
✓ PSA remains undetectable
✓ No recurrence detected
✓ Continue annual surveillance indefinitely
✓ Focus on overall health and quality of life

─────────────────────────────────────────────────────────────────

BEYOND 10 YEARS POST-RARP (2035+): LONG-TERM SURVIVOR PHASE
─────────────────────────────────────────────────────────────────

Why This Phase Matters:
✓ By year 10, if no recurrence, you're likely cured
✓ Risk of recurrence becomes very low
✓ You transition to "cancer survivor" identity
✓ Focus is on overall health and longevity

Your Surveillance Schedule:
├─ PSA Testing: Every 12 months (annual) OR as clinically indicated
├─ Oncology Visits: Every 12-24 months OR as needed
├─ Imaging: Only if PSA elevated or symptoms develop
├─ Digital Rectal Exam: At oncology visits
└─ Total Appointments: 1-2 per year

What You're Watching For:
✓ PSA remains ≤0.010 ng/mL (Excellent)
✓ No PSA elevation or doubling
✓ No new symptoms
✓ Continued stability

Expected Outcome (Most Likely - 95%+):
✓ PSA remains undetectable
✓ No recurrence detected
✓ You're considered "cured" of prostate cancer
✓ Focus on overall health, longevity, and quality of life

─────────────────────────────────────────────────────────────────

WHAT "CURED" MEANS FOR PROSTATE CANCER:

Important Clarification:
In prostate cancer, we don't use the word "cured" the same way
as other cancers. Instead, we use these terms:

✓ "No Evidence of Disease" (NED)
  = No cancer detected on imaging or PSA testing
  = Most common outcome after successful RARP

✓ "Biochemical Recurrence-Free Survival"
  = PSA remains undetectable after treatment
  = Indicates successful treatment

✓ "Cancer Survivor"
  = You've completed treatment and are in surveillance
  = You're living well with your cancer history

For Your Situation:
If your PSA remains ≤0.010 ng/mL for 5-10 years post-RARP:
✓ You have "No Evidence of Disease"
✓ Your cancer is considered "cured" in practical terms
✓ Risk of recurrence becomes very low
✓ You can live a normal lifespan
✓ You should focus on overall health and quality of life

─────────────────────────────────────────────────────────────────

RECURRENCE STATISTICS: WHAT THE DATA SHOWS

According to NCCN (National Comprehensive Cancer Network) Guidelines
and ASCO (American Society of Clinical Oncology) recommendations:

For Localized Prostate Cancer Treated with RARP:

5-Year Biochemical Recurrence-Free Survival:
├─ Low-Risk Disease: 95-98%
├─ Intermediate-Risk Disease: 85-92%
└─ High-Risk Disease: 70-80%

10-Year Biochemical Recurrence-Free Survival:
├─ Low-Risk Disease: 90-95%
├─ Intermediate-Risk Disease: 75-85%
└─ High-Risk Disease: 60-75%

What This Means for You:
✓ Most men remain recurrence-free long-term
✓ Early detection (at PSA level) has excellent outcomes
✓ Your surveillance is designed to catch any recurrence early
✓ If recurrence occurs, treatment options are available

─────────────────────────────────────────────────────────────────

FACTORS THAT AFFECT YOUR RECURRENCE RISK:

Your Oncologist Considers:

1. PATHOLOGY FACTORS (From Your RARP Specimen):
   ✓ Gleason score
   ✓ Tumor stage (pT2, pT3a, pT3b, pT4)
   ✓ Surgical margins (positive vs. negative)
   ✓ Extraprostatic extension